Valo's CEO to Participate in Financial Times U.S. Pharma and Biotech Summit

David Berry to Participate in Panel on Emerging Investment Trends in Therapeutics

Valo Health, LLC (Valo), the tech­nol­o­gy com­pa­ny that is using human-cen­tric data, machine learn­ing com­pu­ta­tion, and life sci­ence exper­tise to trans­form and accel­er­ate the drug dis­cov­ery and devel­op­ment process, today announced that David Berry, Ph.D., founder and Chief Exec­u­tive Offi­cer of Valo will par­tic­i­pate in a pan­el dis­cus­sion dur­ing the Finan­cial Times US Phar­ma and Biotech Sum­mit on Wednes­day, May 5, 2021 at 11:30 AM ET.

The pan­el, Nav­i­gat­ing the phar­ma invest­ment land­scape,” will focus on emerg­ing invest­ment trends in the areas of ther­a­peu­tics, tech­nol­o­gy, and M&A.

About Valo
Valo Health, LLC (Valo) is a tech­nol­o­gy com­pa­ny that is using human-cen­tric data and arti­fi­cial intel­li­gence (AI) com­pu­ta­tion to trans­form the drug dis­cov­ery and devel­op­ment process. As a dig­i­tal­ly native com­pa­ny, Valo is the first to ful­ly inte­grate human-cen­tric data across the entire drug devel­op­ment life­cy­cle into a sin­gle uni­fied archi­tec­ture, there­by accel­er­at­ing the dis­cov­ery and devel­op­ment of life-chang­ing drugs while simul­ta­ne­ous­ly reduc­ing the cost, time, and fail­ure rate. The com­pa­ny’s Opal Com­pu­ta­tion­al Plat­form™, a ful­ly inte­grat­ed, com­pu­ta­tion­al, end-to-end drug devel­op­ment plat­form, offers a unique approach to ther­a­peu­tic devel­op­ment that enables Valo to advance a robust pipeline of can­di­dates across car­dio­vas­cu­lar dis­ease, oncol­o­gy, and neu­rode­gen­er­a­tion. Found­ed by Flag­ship Pio­neer­ing and head­quar­tered in Boston, MA, Valo has offices in Lex­ing­ton, MA, San Fran­cis­co, CA, Prince­ton, NJ, and in Bran­ford, CT. To learn more, vis­it www​.val​o​health​.com.